CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to discover new drug targets for treating various forms of anemia, particularly those resistant to erythropoietin. It also seeks to elucidate the mechanisms behind Diamond-Blackfan anemia using a novel animal model to develop effective therapies.
More than a billion people suffer from anemia.
The only drug used to symptomatically increase red blood cell production in anemic patients is recombinant erythropoietin (Epo).
While Epo injections effectively promote red blood cell production in patients suffering low endogenous Epo production, aplastic anemia and anemia associated with cancer, inflammation and infection do not respond well to recombinant Epo treatment.Aim A:
Since there is a great need for new drugs that can treat Epo-resistant…
MAX IV Laboratory, Lund University
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
